ClinicalTrials.gg
TerminatedNCT06571708NeoSTOP-ITUpdated Nov 3, 2026Results posted

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

A Phase 2 interventional study of Gemcitabine and Cisplatin in Bladder Cancer and Muscle-Invasive Bladder Carcinoma, sponsored by Columbia University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Columbia University · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Change in standard of care treatment for muscle-invasive bladder cancer
Updated Nov 3, 2026Now TerminatedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies testing gemcitabine in Urinary Bladder Neoplasms — 12 open to participants now, 23 under way, 3 of them phase 3. Gemcitabine · Urinary Bladder Neoplasms.

Enrollment
93rd of 96
1 · median 42
Started
2025
with 5 others
Phase 2
61 of 101
7 open now
Registered
92nd of 101
by date

Among the 101 studies testing gemcitabine in Urinary Bladder Neoplasms, this one is the 93rd largest by enrollment of the 96 interventional ones that give a count, is one of 6 that started in 2025, is one of 61 in phase 2, and was the 92nd registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

12 of the 101 studies testing gemcitabine in Urinary Bladder Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing gemcitabine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults. The main question it aims to answer is: Can gemcitabine, cisplatin, and cemiplimab with or without fianlimab treat bladder cancer?

Participants will be randomly selected (like the loss of a coin) to treatment with gemcitabine, cisplatin, cemiplimab, and fianlimab or gemcitabine, cisplatin, and cemiplimab.

Participants will:

  • Undergo transurethral resection of bladder tumor (TURBT) followed by the start of treatment, receive 4 cycles of treatment (21 day cycles)
  • After 4 cycles of treatment, patients will undergo repeat maximal TURBT with imaging
  • Participants with a complete response will continue maintenance cemiplimab or cemiplimab/fianlimab for 13 more cycles with imaging every 3 months
  • Participants without a complete clinical response will undergo cystectomy (bladder surgery).
Read the detailed description

This is a phase 2, open-label, randomized trial with continuous toxicity monitoring to ensure safety using Bayesian toxicity monitoring, which will evaluate treatment with doublet platinum-based chemotherapy (gemcitabine and cisplatin) plus cemiplimab (REGN2810) with or without fianlimab (REGN3767) for localized muscle-invasive bladder cancer (MIBC). Participants will be randomized to 4 cycles of 3 weeks each (12 weeks total) with gemcitabine, cisplatin, and cemiplimab with or without fianlimab. Participants achieving a clinical complete response will continue 13 more cycles of immunotherapy (39 weeks total). The total duration of systemic treatment, including neoadjuvant therapy, will be 52 weeks.

In addition to the actual time on treatment, there will be time off treatment for recovery after neoadjuvant treatment and before adjuvant treatment. First, between the neoadjuvant phase and cystoscopy (with TURBT for residual disease), there will be up to 4 weeks off treatment. In between the cystoscopy/TURBT and start of adjuvant immunotherapy, there will be an additional up to 4 week interval for recovery. Participants will have regularly scheduled study visits at the clinical site on Day 1 and Day 8 of every three-week cycle in the neoadjuvant setting, where continuous assessment, including treatment response and safety assessments, will be performed. These will include laboratory tests, taking of vital signs, and physical examinations. In the adjuvant setting for participants who continue to maintenance immunotherapy, participants will have regularly scheduled study visits at the clinical site on Day 1 of every three-week cycle.

Response to treatment will be determined by three modalities. First, CT scans (chest, abdomen, and pelvis with and without contrast) to ensure no metastatic disease. For participants who are unable to get a CT scan w/ contrast due to renal function (or any other reason), an MRI with and without contrast may be used instead. Scans are required at baseline and every 3 months in the adjuvant setting for participants who continue on with maintenance immunotherapy. Second, all participants will undergo post-treatment cystoscopy every 3 months while on treatment. Third, all participants will undergo post-treatment urine cytology every 3 months while on treatment.

03

Conditions studied

  • Bladder Cancer
  • Muscle-Invasive Bladder Carcinoma

Keywords

  • Urothelial Predominant Histology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written for the trial.
  • Age ≥18 years of age on day of signing informed consent.
  • > 12 months.
  • Performance status of 0-1 using the (ECOG) Performance Scale.
  • confirmed muscle-invasive urothelial carcinoma of the bladder defined as T2-T3, N0, M0 stage. Mixed histology is permitted if there is a urothelial component. Upper tract disease in not permitted.
  • Prior Bacillus Calmette-Guerin (BCG) or other intravesical treatment of non-muscle invasive bladder cancer is permitted if completed at least 6 weeks prior to initiating study treatment. Only one course (includes induction + maintenance) of BCG or intravesical therapy is permitted.
  • No disease based on cross-sectional imaging.
  • Considered cisplatin eligible based on protocol specified criteria.
  • Not received any or neoadjuvant chemotherapy or immunotherapy.
  • Agree to pre- and post-treatment TURBT as well as surveillance with cystoscopies, cross-sectional imaging, and urine cytology unless medically in the opinion of the treating physician, and discussed with the principal investigator

Exclusion criteria

Exclusion Criteria:

  • Concurrent upper urinary tract (i.e., ureter, renal pelvis) invasive urothelial carcinoma. (NOTE: Patients with history of non-invasive (Ta, Tis) upper tract urothelial carcinoma that has been definitively treated with at least one post- treatment disease assessment (i.e. cytology, , imaging) that demonstrates no evidence of residual disease are eligible).
  • Received prior (including anti-PD-1, anti-PD-L1, anti-CTLA4, anti-LAG-3 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways ), as well as cellular vaccines, cellular therapies, or systemic oncolytic virus therapy.
  • Received bladder-directed radiation therapy previously for bladder cancer.
  • Received prior systemic chemotherapy for muscle-invasive bladder cancer.
  • Receiving any other agents concurrently or within 4 weeks of start of treatment.
  • Had a solid organ or hematologic transplant.
  • Ongoing or recent (within 2 years) evidence of an disease that required systemic treatment with agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment
  • Has a diagnosis of immunodeficiency or is receiving systemic therapy (at a dose greater than 10mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
  • Has a history of myocarditis.
  • Patients with another active second other than non-melanoma skin cancers.
  • Has a known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
  • Has an active infection requiring systemic therapy.
  • History or current evidence of significant ( (CTCAE) grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication.
  • Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator, including dialysis.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Uncontrolled infection with (HIV), virus (HBV), or virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection.
  • Is pregnant or is a breastfeeding woman.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Group 1: Gemcitabine/Cisplatin/Cemiplimab

    * Gemcitabine 1000 mg/m\^2 IV (days 1 and 8 of 21 day for 4 cycles) * Cisplatin 70 mg/m\^2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose -cisplatin 35 m/m\^2 IV (day 1 and 8 of 21 day cycle for 4 cycles) * Cemiplimab (REGN 2810) 350 mg IV every 3 weeks (17 cycles)

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Cemiplimab

  • Experimental
    Group 2: Gemcitabine/Cisplatin/Cemiplimab/Fianlimab

    * Gemcitabine 1000 mg/m2 IV (days 1 and 8 of 21 day cycle for 4 cycles) * Cisplatin 70 mg/m2 IV (day 1 of 21 day cycle for 4 cycles) or renally-dosed split-dose cisplatin 35 m/m2 IV (day 1 and 8 of 21 day cycle for 4 cycles ) * Cemiplimab (REGN 2810) 350mg IV every 3 weeks (4 cycles) * Fianlimab (REGN3767) 1600mg IV every 3 weeks (4 cycles)

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Cemiplimab · Drug: Fianlimab

Interventions

  • Gemcitabine 1000 mg/m\^2 IV

  • Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV

  • Cemiplimab 350mg IV

    Also known as: REGN 2810

  • Fianlimab 1600mg IV

    Also known as: REGN3767

06

What researchers measure

Primary outcomes

  1. Clinical Complete Response

    Rate of clinical complete response after 4 cycles of neoadjuvant chemoimmunotherapy. Complete clinical response will be defined as: * No high-grade malignancy on repeat TURBT * No malignant cells on urine cytology * No definitive evidence of invasive local or metastatic disease on cross-sectional imaging (CT chest, abdomen, and pelvis with contrast or, if renal dysfunction, MRI with contrast) Cytoscopy and imaging should occur within 4 weeks of end of neoadjuvant therapy.

    Time frame: 16 weeks

Secondary outcomes

  1. Number of Adverse Events

    Defined as the occurrence of any adverse event (AE) related to the investigational drugs at any point on treatment until 30 days after the last dose of treatment. AEs as evaluated per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: 30 days after last dose of treatment, up to 56 weeks

  2. Bladder-intact Survival

    Bladder-intact survival is defined as the time from start of treatment until cystectomy or death.

    Time frame: Up to 5 years

  3. Recurrence-free Survival

    Recurrence-free survival is defined as the time from start of treatment until disease recurrence or death. Recurrence-survival will only be measured in patients who achieve a clinical complete response.

    Time frame: Up to 5 years

  4. Overall Survival

    Overall survival is defined as the time from start of treatment until death.

    Time frame: Up to 5 years

07

Results

Posted Nov 3, 2026
Limitations and caveats
This study was closed due to a change in standard of care treatment for muscle-invasive bladder cancer making the study design obsolete. This study was not closed due to any safety issues.

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started1
Completed1
Not completed0

Outcome measures

PrimaryClinical Complete Response

Rate of clinical complete response after 4 cycles of neoadjuvant chemoimmunotherapy. Complete clinical response will be defined as: * No high-grade malignancy on repeat TURBT * No malignant cells on urine cytology * No definitive evidence of invasive local or metastatic disease on cross-sectional imaging (CT chest, abdomen, and pelvis with contrast or, if renal dysfunction, MRI with contrast) Cytoscopy and imaging should occur within 4 weeks of end of neoadjuvant therapy.

Time frame:
16 weeks

No measurements were reported for this outcome.

SecondaryNumber of Adverse Events

Defined as the occurrence of any adverse event (AE) related to the investigational drugs at any point on treatment until 30 days after the last dose of treatment. AEs as evaluated per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Time frame:
30 days after last dose of treatment, up to 56 weeks

No measurements were reported for this outcome.

SecondaryBladder-intact Survival

Bladder-intact survival is defined as the time from start of treatment until cystectomy or death.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryRecurrence-free Survival

Recurrence-free survival is defined as the time from start of treatment until disease recurrence or death. Recurrence-survival will only be measured in patients who achieve a clinical complete response.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival is defined as the time from start of treatment until death.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

Adverse events

Collected over 30 days after last dose of treatment, up to 20 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants———

Baseline characteristics

Data was not analyzed or disclosed in an effort to protect participant confidentiality (n=1).

Age, Continuous
Age, ContinuousAll Participants
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female—
Male—
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)All Participants
Region of Enrollment
Region of Enrollment(participants)All Participants
08

Study locations

1 site
  • Columbia University Irving Medical Center/ New York Presbyterian Hospital
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2025 to primary completion in Jan 2026, 4 months.

Results were first posted in Nov 2026, 9 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2028 → Jan 2026 and completion Dec 2028 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 26, 2024
StartActual
Aug 14, 2025
Primary completionActual
Jan 5, 2026was Dec 2028
CompletionActual
Jan 5, 2026was Dec 2028
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Change in standard of care treatment for muscle-invasive bladder cancer
changed Nov 3, 2026
Results
Results posted
posted Nov 3, 2026
Primary completion
Dec 2028→Jan 5, 2026 (actual)
Nov 3, 2026
Study completion
Dec 2028→Jan 5, 2026 (actual)
Nov 3, 2026
Enrollment
36 (estimated)→1 (actual)
Nov 3, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedBladder-intact survivalSurvivalTime frame: Up to 5 years
  • EditedRecurrence-free survivalSurvivalTime frame: Up to 5 years
  • EditedOverall survivalSurvivalTime frame: Up to 5 years
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Terminated
    Why stopped Change in standard of care treatment for muscle-invasive bladder cancer
    Results posted
    Primary completion Dec 2028→Jan 5, 2026 (now actual)
    Study completion Dec 2028→Jan 5, 2026 (now actual)
    Enrollment 36 (estimated)→1 (actual)
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedBladder-intact survivalSurvivalTime frame: Up to 5 years
    • EditedRecurrence-free survivalSurvivalTime frame: Up to 5 years
    • EditedOverall survivalSurvivalTime frame: Up to 5 years
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06571708
Responsible party
Alexander Z. Wei, MD (Assistant Professor of Medicine at the Columbia University Medical Center, Columbia University) — Principal investigator
First posted
Aug 26, 2024
Start date
Aug 14, 2025
Primary completion
Jan 5, 2026
Completion
Jan 5, 2026
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Alexander Z Wei, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin · Cemiplimab

Start the discussion